Cargando…
Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up
To document anxiety and depression from pretreatment till 5-year follow-up in 299 men with localized prostate cancer. To assess, if baseline scores were predictive for anxiety and depression at 1-year follow-up. Respondents completed four assessments (pretreatment, at 6 and 12 months, and at 5-year...
Autores principales: | , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group
2006
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361242/ https://www.ncbi.nlm.nih.gov/pubmed/16622434 http://dx.doi.org/10.1038/sj.bjc.6603057 |
_version_ | 1782153168283500544 |
---|---|
author | Korfage, I J Essink-Bot, M-L Janssens, A C J W Schröder, F H de Koning, H J |
author_facet | Korfage, I J Essink-Bot, M-L Janssens, A C J W Schröder, F H de Koning, H J |
author_sort | Korfage, I J |
collection | PubMed |
description | To document anxiety and depression from pretreatment till 5-year follow-up in 299 men with localized prostate cancer. To assess, if baseline scores were predictive for anxiety and depression at 1-year follow-up. Respondents completed four assessments (pretreatment, at 6 and 12 months, and at 5-year follow-up) on anxiety, depression and mental health. Respondents were subdivided according to therapy (prostatectomy or radiotherapy) and high vs low-anxiety. Pretreatment 28% of all patients were classified as ‘high-anxiety’; their average anxiety scores decreased significantly post-treatment, that is towards less anxiety. At all assessments, high-anxiety men treated by prostatectomy reported less depression than high-anxiety men treated by radiotherapy. Of men treated by radiotherapy, 27% reported clinical significant levels of depression while 20% is expected in a general population. The improvement in mental health at 6-months follow-up was statistically significant and clinically meaningful in all respondent groups. Sensitivity of anxiety at baseline as a screening tool was 71% for anxiety and 60% for symptoms of depression. We recommend clinicians to attempt early detection of patients at risk of high levels of anxiety and depression after prostate cancer diagnosis since prevalence is high. STAI-State can be a useful screening tool but needs further development. |
format | Text |
id | pubmed-2361242 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2006 |
publisher | Nature Publishing Group |
record_format | MEDLINE/PubMed |
spelling | pubmed-23612422009-09-10 Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up Korfage, I J Essink-Bot, M-L Janssens, A C J W Schröder, F H de Koning, H J Br J Cancer Clinical Study To document anxiety and depression from pretreatment till 5-year follow-up in 299 men with localized prostate cancer. To assess, if baseline scores were predictive for anxiety and depression at 1-year follow-up. Respondents completed four assessments (pretreatment, at 6 and 12 months, and at 5-year follow-up) on anxiety, depression and mental health. Respondents were subdivided according to therapy (prostatectomy or radiotherapy) and high vs low-anxiety. Pretreatment 28% of all patients were classified as ‘high-anxiety’; their average anxiety scores decreased significantly post-treatment, that is towards less anxiety. At all assessments, high-anxiety men treated by prostatectomy reported less depression than high-anxiety men treated by radiotherapy. Of men treated by radiotherapy, 27% reported clinical significant levels of depression while 20% is expected in a general population. The improvement in mental health at 6-months follow-up was statistically significant and clinically meaningful in all respondent groups. Sensitivity of anxiety at baseline as a screening tool was 71% for anxiety and 60% for symptoms of depression. We recommend clinicians to attempt early detection of patients at risk of high levels of anxiety and depression after prostate cancer diagnosis since prevalence is high. STAI-State can be a useful screening tool but needs further development. Nature Publishing Group 2006-04-24 2006-04-04 /pmc/articles/PMC2361242/ /pubmed/16622434 http://dx.doi.org/10.1038/sj.bjc.6603057 Text en Copyright © 2006 Cancer Research UK https://creativecommons.org/licenses/by/4.0/This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material.If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit https://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Clinical Study Korfage, I J Essink-Bot, M-L Janssens, A C J W Schröder, F H de Koning, H J Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
title | Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
title_full | Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
title_fullStr | Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
title_full_unstemmed | Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
title_short | Anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
title_sort | anxiety and depression after prostate cancer diagnosis and treatment: 5-year follow-up |
topic | Clinical Study |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2361242/ https://www.ncbi.nlm.nih.gov/pubmed/16622434 http://dx.doi.org/10.1038/sj.bjc.6603057 |
work_keys_str_mv | AT korfageij anxietyanddepressionafterprostatecancerdiagnosisandtreatment5yearfollowup AT essinkbotml anxietyanddepressionafterprostatecancerdiagnosisandtreatment5yearfollowup AT janssensacjw anxietyanddepressionafterprostatecancerdiagnosisandtreatment5yearfollowup AT schroderfh anxietyanddepressionafterprostatecancerdiagnosisandtreatment5yearfollowup AT dekoninghj anxietyanddepressionafterprostatecancerdiagnosisandtreatment5yearfollowup |